Lotus Eye Hospit (LOTUSEYE)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Debt/Equity is only 0.08, so the balance sheet is conservatively financed.
• Revenue growth of 10.61% shows the hospital business is expanding at the topline.
• Promoter holding of 39.67% provides some alignment with public shareholders.
• Book value of ₹28.17 gives a tangible asset base, though price is far above it.

Concerns

• Extremely low profitability: ROE 1.08%, ROCE 2.99%, latest quarter net profit ~₹0 Cr.
• Profit declined 8.33% despite sales growth, indicating no operating leverage.
• Very expensive valuation: P/E 352.54, P/B 4.51, PEG 33.23.
• Piotroski F-score 4/9 and zero dividend yield offer little support to minority investors.

AI Analysis

At ₹127.05, Lotus Eye Hospit is a business I would circle but not buy. The balance sheet is conservative—debt/equity is just 0.08—and sales grew 10.61%, but that is where the good news ends. This company earned an ROE of only 1.08% and ROCE of 2.99%. In the latest quarter, sales were ₹14 Cr and net profit was essentially ₹0 Cr. Over the year, profit actually fell 8.33%. As Graham said, the stock market is a voting machine in the short run and a weighing machine in the long run; on these numbers, the weighing machine says the business generates almost no earnings. The market cap is ₹229 Cr, so investors are paying about 352 times earnings and 4.51 times book value for a business that earns almost nothing. Book value is only ₹28.17. There is no dividend yield, so minority shareholders receive no cash while waiting. The Piotroski F-score of 4/9 raises further doubts about financial strength. Promoter holding of 39.67% is decent, but it does not compensate for weak profitability. The 52-week range of ₹75.51 to ₹153.00 shows a volatile speculative stock, not a stable compounding machine. Is this a turnaround? Possibly, if margins recover and profit turns positive. But I do not pay a premium for 'possibly.' I need a margin of safety—at 127 rupees, there is none for an owner with such low return on capital.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer